Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Benjamin Tomlinson
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06129734CT.gov Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | — | Recruiting | — | — | — |
NCT07044544CT.gov Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | — | Recruiting | — | — | — |
NCT05455294CT.gov Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT03855371CT.gov Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | Benjamin Tomlinson | P2 | BB · 64 |
| Cytarabine | First Affiliated Hospital of Zhejiang University | P3 | BBB |
| Mitoxantrone | First Affiliated Hospital of Zhejiang University | P3 | BBB |
| Cladribine | University of Washington | P2 | BBB |
| Cyclophosphamide | Prelude Therapeutics | P3 | BB |
| Idarubicin | Northwestern University | P3 | BB |
| Venetoclax | First Affiliated Hospital of Zhejiang University | P3 | BB |
| Recombinant Human Granulocyte Colony-Stimulating Factor | University of Washington | P2 | BB |
| Fludarabine | First Affiliated Hospital of Zhejiang University | P3 | BB |
+38 more in the Myeloid Neoplasm cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Myeloid Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-myeloid-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →